Clearmind Medicine Inc. (NASDAQ:CMND) Short Interest Up 351.5% in February

Clearmind Medicine Inc. (NASDAQ:CMND) was the target of a significant growth in short interest in February. As of February 13th, there was short interest totaling 132,651 shares, a growth of 351.5% from the January 29th total of 29,379 shares. Currently, 8.8% of the shares of the stock are short sold. Based on an average daily volume of 809,368 shares, the short-interest ratio is presently 0.2 days. Based on an average daily volume of 809,368 shares, the short-interest ratio is presently 0.2 days. Currently, 8.8% of the shares of the stock are short sold.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Clearmind Medicine to a “sell” rating in a research note on Saturday, December 20th.

Clearmind Medicine Stock Performance

CMND stock opened at $1.17 on Thursday. Clearmind Medicine has a one year low of $1.05 and a one year high of $52.40. The firm has a market cap of $1.76 million, a PE ratio of -0.04 and a beta of 1.35. The firm’s 50 day moving average price is $2.02 and its 200-day moving average price is $20.18.

Clearmind Medicine (NASDAQ:CMND) last posted its earnings results on Tuesday, January 20th. The company reported ($4.75) earnings per share (EPS) for the quarter.

Institutional Trading of Clearmind Medicine

A hedge fund recently raised its stake in Clearmind Medicine stock. AdvisorShares Investments LLC raised its stake in Clearmind Medicine Inc. (NASDAQ:CMND) by 9.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 224,378 shares of the company’s stock after buying an additional 18,445 shares during the quarter. AdvisorShares Investments LLC owned about 4.10% of Clearmind Medicine worth $230,000 at the end of the most recent quarter. Institutional investors and hedge funds own 96.05% of the company’s stock.

About Clearmind Medicine

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.